Article Text

other Versions

PDF
Intravitreal Bevacizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion
  1. Thomas C Kreutzer (thomas.kreutzer{at}med.uni-muenchen.de),
  2. Claudia S Alge (claudia.alge{at}med.uni-muenchen.de),
  3. Armin H Wolf (armin.wolf{at}med.uni-muenchen.de),
  4. Daniel Kook (daniel.kook{at}med.uni-muenchen.de),
  5. Johannes Burger (johannes.burger{at}med.uni-muenchen.de),
  6. Rupert Strauß (rupert.strauss{at}med.uni-muenchen.de),
  7. Christian Kunze (christian.kunze{at}i-med.ac.at),
  8. Christos Haritoglou (christos.haritoglou{at}med.uni-muenchen.de),
  9. Anselm Kampik (anselm.kampik{at}med.uni-muenchen.de),
  10. Siegfried G Priglinger (siegfried.priglinger{at}med.uni-muenchen.de)
  1. LMU Munich, Germany
  2. LMU Munich, Germany
  3. LMU Munich, Germany
  4. LMU Munich, Germany
  5. LMU Munich, Germany
  6. LMU Munich, Germany
  7. University Innsbruck, Austria
  8. LMU Munich, Germany
  9. LMU Munich, Germany
  10. LMU Munich, Germany

    Abstract

    Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin®) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion (BRVO).

    Methods: A prospective, non comparative, consecutive, interventional case series of thirty four patients. Patients received repeated intravitreal injections of 1.25mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and optical coherence tomography measurements in a follow up period of 6 months.

    Results: Patients presented at a mean age of 69 years (range 44 – 86 years). Mean duration of symptoms was 40 weeks (range 1 – 300 weeks). Visual acuity at baseline was 0.79 LogMAR (±0.39) and improved to a mean of 0.46 LogMAR (±0.38) at the six month control (P = 0.009). Mean letter score on the ETDRS-chart at baseline was 45.3 (±19.0) and improved to a mean of 65.3 (±20.6) letters at the six month control visit (P = 0.003). Retinal thickness as measured by OCT at baseline was 473µm (±120) and declined to a mean of 326µm (±90) at the six month control.

    Conclusion: Intravitreal injection of 1.25mg bevacizumb appears to be an effective treatment option for BRVO.

    • Retina
    • Macula
    • Branch retinal vein occlusion
    • bevacizumab
    • macula oedema

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • At a glance
      Harminder S Dua Arun D Singh, Editors-in-Chief